Earnings Call · Q3 FY2022·2022-11-02

Q3 22EPS +4.71%·Rev n/aQ2 22EPS +2.50%·Rev n/aQ1 22EPS +6.33%·Rev n/aQ4 21EPS +15.28%·Rev n/a⚠ consensus missing

Editas Medicine, Inc. EDIT

Ron Moldaver

Gilmore O’Neill

Baisong Mei — Chief Medical Officer

Mark Shearman — Chief Scientific Officer

Michelle Robertson — Chief Financial Officer

+1.1%1d on move date+3.6% vs SPY3d−9.8%5d−12.0%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more EDIT calls or request research access.

More EDIT calls Browse calls Request research access